IMMP News and Press, Immutep Limited

A look at the top 10 most actives in the United States iSpecimen Inc. (ISPC) rose 27.0% to $0.2844 on volume of 264,529,162 shares bioAffinity Technologies Inc. (BIAF) rose 98.1% to $2.12 on volume of 238,230,568 shares Functional Brands Inc. (MEHA) rose 0.9% to $0.193 on volume of 185,024,...

A look at the top 10 most actives in the United States iSpecimen Inc. (ISPC) rose 77.1% to $0.3968 on volume of 159,189,677 shares bioAffinity Technologies Inc. (BIAF) rose 115.4% to $2.305 on volume of 87,353,377 shares CXApp Inc. (CXAI) rose 33.1% to $0.2928 on volume of 76,335,147 shares...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), today announced that the ...

2026-03-13 06:53:07 ET More on Immutep Seeking Alpha’s Quant Rating on Immutep Historical earnings data for Immutep Financial information for Immutep Read the full article on Seeking Alpha For further details see: Immutep halts late-stage t...

The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respe...

Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater China In January 2026, Immutep received ~A$30 million upfront payment from Dr. Reddy’s and is e...

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels Dose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profile Substantial reduction in T cell activity highlights the potential eff...

The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolment Strong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the Unite...

Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive pot...

Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and immune activation in heavily pretreated metastatic breast cancer patients AIPAC-003 has resulted in successful completion of FDA’s Project Optimus requirements an...